Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA E542K VS-5584 colon adenocarcinoma sensitive detail...
BRAF V600E N/A colon adenocarcinoma not applicable detail...
BRAF L597Q Trametinib colon adenocarcinoma predicted - sensitive detail...
BRAF L597Q Selumetinib colon adenocarcinoma predicted - sensitive detail...
BRAF L597Q Sapitinib colon adenocarcinoma predicted - sensitive detail...
BRAF L597Q Cetuximab + Trametinib colon adenocarcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Regorafenib + Trametinib colon adenocarcinoma predicted - sensitive detail...
EML4 - ALK Alectinib colon adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK L1319V Alectinib colon adenocarcinoma predicted - resistant detail...
ATM Q628Pfs*7 ATM I1581Nfs*5 ATM A2843V RP-3500 colon adenocarcinoma sensitive detail...
BRAF V600E MAP2K1 D67N Vemurafenib colon adenocarcinoma resistant detail...
BRAF V600E MAP2K1 P124S Vemurafenib colon adenocarcinoma resistant detail...
BRAF V600E MAP2K1 G128D Vemurafenib colon adenocarcinoma resistant detail...
BRAF V600E MAP2K1 E203K Vemurafenib colon adenocarcinoma resistant detail...
BRAF V600E MAP2K1 D67N Cobimetinib colon adenocarcinoma resistant detail...
BRAF V600E MAP2K1 P124S Cobimetinib colon adenocarcinoma resistant detail...
BRAF V600E MAP2K1 G128D Cobimetinib colon adenocarcinoma resistant detail...
BRAF V600E MAP2K1 E203K Cobimetinib colon adenocarcinoma resistant detail...
BRAF V600E MAP2K1 L115P Cobimetinib colon adenocarcinoma resistant detail...
BRAF V600E MAP2K1 I99_K104del Cobimetinib colon adenocarcinoma resistant detail...
BRAF V600E Cetuximab + Dabrafenib + Trametinib colon adenocarcinoma predicted - sensitive detail...
BRAF V47_M438del BRAF V600E Cetuximab + Irinotecan + Vemurafenib colon adenocarcinoma predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00602329 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer Terminated USA 0
NCT01001377 Phase III Cetuximab Panitumumab ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed USA | NLD | ITA | GBR | FRA | CAN | BEL | AUS 21
NCT01103323 Phase III Regorafenib Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy Completed USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT01206530 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab Hydroxychloroquine FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Completed USA 0
NCT01298570 Phase II Fluorouracil + Irinotecan + Leucovorin Regorafenib Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer Completed USA 1
NCT01442935 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases Completed FRA 0
NCT01471353 Phase II Capecitabine + Sorafenib Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer Completed USA 0
NCT01516216 Phase II Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Study of Vitamin D in Untreated Metastatic Colorectal Cancer Completed USA 0
NCT01538680 Phase III Regorafenib Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy No longer available USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT01571284 Phase III Aflibercept + Fluorouracil + Irinotecan + Leucovorin Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Completed USA | NLD | ITA | GBR | ESP | DEU | CAN | BEL 15
NCT01652482 Phase II Cetuximab Duligotuzumab Fluorouracil + Irinotecan + Leucovorin A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed USA | NZL | ITA | GBR | FRA | ESP | DEU | BEL | AUS 1
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed USA 0
NCT01814501 Phase II Fluorouracil + Irinotecan + Leucovorin Panitumumab Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab Unknown status USA 0
NCT01896856 Phase Ib/II Guadecitabine + Irinotecan Regorafenib Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer Completed USA | NLD 0
NCT01910610 Phase III Cetuximab Irinotecan + Panitumumab Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine + Oxaliplatin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1) Active, not recruiting FRA 2
NCT01939223 Phase III Regorafenib COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 5
NCT01949194 Phase II Regorafenib Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Unknown status CAN 0
NCT02008383 Phase I Cabozantinib + Panitumumab Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer Completed USA 0
NCT02045030 Phase II Aflibercept + Fluorouracil + Irinotecan + Leucovorin Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Terminated CAN 0
NCT02046538 Phase II Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Aflibercept Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer Withdrawn USA 0
NCT02096354 Phase II Regorafenib A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer Completed USA 0
NCT02119676 Phase II Regorafenib Ruxolitinib Study of Ruxolitinib in Colorectal Cancer Patients Terminated USA | GBR | FRA | ESP | DEU | AUS 2
NCT02138617 Phase II Leucovorin Bevacizumab Irinotecan Fluorouracil Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT02164916 Phase II Cetuximab + Irinotecan Cetuximab + Irinotecan + Vemurafenib S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Completed USA 0
NCT02195011 Phase II Regorafenib Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases Completed USA 0
NCT02305758 Phase II Fluorouracil + Irinotecan + Leucovorin Bevacizumab Veliparib Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer Completed 0
NCT02368886 Phase II Clobetasol + Regorafenib Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer Completed USA 0
NCT02384759 Phase II Aflibercept + Fluorouracil + Leucovorin Fluorouracil + Leucovorin Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers (FOLFA) Completed FRA 0
NCT02393755 Phase Ib/II Capecitabine + Nintedanib Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer Completed USA 0
NCT02450175 Phase I Letrozole Everolimus Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls Unknown status USA 0
NCT02575508 Phase Ib/II Fluorouracil + Infigratinib + Irinotecan + Oxaliplatin Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer Withdrawn USA 0
NCT02581059 Phase II Regorafenib Efficacy of Ginseng for Patients on Regorafenib Terminated USA 0
NCT02651415 Phase II Perindopril + Regorafenib Phase II Study of Perindopril and Regorafenib in mCRC Completed CAN 0
NCT02664077 Phase III Regorafenib A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer (ARGO) Terminated USA 0
NCT02687009 Phase I Niclosamide A Study of Niclosamide in Patients With Resectable Colon Cancer Terminated USA 0
NCT02788279 Phase III Atezolizumab Atezolizumab + Cobimetinib Regorafenib A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma Completed USA | ITA | GBR | ESP | CAN | BEL | AUS 4
NCT02912559 Phase III Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Active, not recruiting USA | DEU 1
NCT02934529 Phase III Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Capecitabine + Fluorouracil + Leucovorin Regorafenib Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (AIO-KRK-0114) Active, not recruiting DEU 0
NCT02972034 Phase I MK-8353 + Pembrolizumab Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) Completed USA | CAN 0
NCT02997228 Phase III Atezolizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer Recruiting USA 0
NCT03026140 Phase II Ipilimumab + Nivolumab Celecoxib + Ipilimumab + Nivolumab Nivolumab + Relatlimab BMS-986253 + Nivolumab Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (NICHE) Recruiting NLD 0
NCT03043313 Phase II Trastuzumab + Tucatinib Tucatinib Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Completed USA | ITA | FRA | ESP | BEL 0
NCT03144804 Phase II Lamivudine A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Completed USA 0
NCT03261947 Phase II Simurosertib A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Completed USA 1
NCT03279289 Phase II Aflibercept + Fluorouracil + Irinotecan + Leucovorin Aflibercept + Fluorouracil + Leucovorin Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen (AFEMA) Completed ESP 0
NCT03365882 Phase II Cetuximab + Irinotecan Pertuzumab + Trastuzumab S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 1
NCT03368859 Phase II ABT-165 + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab Terminated USA | ESP | CAN | BEL 2
NCT03436563 Phase Ib/II Bintrafusp alfa M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Active, not recruiting USA 0
NCT03520946 Phase III Ramucirumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS) Active, not recruiting DEU 0
NCT03592641 Phase II Savolitinib Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Terminated USA 0
NCT03635021 Phase III Fluorouracil + Irinotecan + Leucovorin + Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (CR-SEQUENCE) Active, not recruiting ESP 0
NCT03692429 Phase I Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NKR-2 cells alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK) Recruiting USA | BEL 0
NCT03801915 Phase II MVT-5873 Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Completed USA 0
NCT03803553 Phase III Binimetinib + Cetuximab + Encorafenib Nivolumab Fluorouracil + Irinotecan + Leucovorin Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer Recruiting USA 0
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed USA | CAN 0
NCT03829462 Phase III Regorafenib Irinotecan + Regorafenib Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI) Recruiting FRA 0
NCT03866239 Phase I Atezolizumab + Obinutuzumab + RO6958688 A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma Completed USA | FRA | ESP 1
NCT03867799 Phase II Nivolumab + Relatlimab iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer Active, not recruiting GBR 0
NCT03948763 Phase I mRNA 5671 mRNA 5671 + Pembrolizumab A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) Completed USA | NZL | AUS 4
NCT03992456 Phase II Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Active, not recruiting USA 0
NCT04017650 Phase Ib/II Cetuximab + Encorafenib + Nivolumab Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Recruiting USA 0
NCT04034173 Phase II Fluorouracil + Irinotecan + Leucovorin + Panitumumab Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation Not yet recruiting DEU 0
NCT04034459 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116) Active, not recruiting DEU 0
NCT04044430 Phase Ib/II Binimetinib + Encorafenib + Nivolumab Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Terminated USA 0
NCT04109924 Phase II Bevacizumab + Irinotecan + Trifluridine-tipiracil hydrochloride TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Active, not recruiting USA 0
NCT04126733 Phase II Nivolumab + Regorafenib Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) Completed USA 0
NCT04158349 Phase I Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer (IPOX-FOLFIRI) Terminated USA 0
NCT04169347 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer Active, not recruiting USA 0
NCT04231526 Phase II Pembrolizumab Pembrolizumab in Early Stage Colon Cancer Recruiting USA 0
NCT04282044 Phase I CRX100 Study of CRX100 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04362839 Phase I Ipilimumab + Nivolumab + Regorafenib Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT04450836 Phase II Regorafenib + Trifluridine-tipiracil hydrochloride Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT) Active, not recruiting FRA | BEL 0
NCT04479436 Phase II Patritumab deruxtecan A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer Terminated USA | ITA | GBR | FRA | ESP | BEL 2
NCT04495621 Phase Ib/II Cetuximab + MEN1611 MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (C-PRECISE-01) Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU 1
NCT04554836 Phase II Cetuximab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab Active, not recruiting DEU 0
NCT04579757 Phase Ib/II Surufatinib + Tislelizumab Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04599140 Phase Ib/II Nivolumab + SX-682 SX-682 SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial Recruiting USA 0
NCT04607668 Phase III Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Trilaciclib Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1) Terminated USA | ITA | GBR | ESP 4
NCT04616183 Phase Ib/II Abemaciclib + Cetuximab + LY3214996 Cetuximab + LY3214996 LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT04689347 Phase I Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Temozolomide 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. Unknown status ITA 0
NCT04737187 Phase III Bevacizumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT) Completed USA | ITA | FRA | ESP | DEU | BEL | AUT 7
NCT04826003 Phase Ib/II Obinutuzumab + RO6958688 + RO7122290 Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment Active, not recruiting NLD | GBR | ESP 2
NCT04929223 Phase I Bevacizumab + Inavolisib Cetuximab + Inavolisib A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (Intrinsic) Recruiting USA | ITA | GBR | ESP | DEU | CAN | AUS 4
NCT04991948 Phase I Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin + Pembrolizumab Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer Recruiting USA | BEL 0
NCT05007132 Phase II Bevacizumab + Trifluridine-tipiracil hydrochloride Panitumumab + Trifluridine-tipiracil hydrochloride Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer Recruiting DEU 0
NCT05062889 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin Trifluridine-tipiracil hydrochloride Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (ERASE-CRC) Recruiting ITA 0
NCT05118724 Phase II Atezolizumab Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin (ANTONIO) Recruiting DEU 0
NCT05130060 Phase I PolyPEPI1018 + Trifluridine-tipiracil hydrochloride A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer Completed USA 0
NCT05178576 Phase II XOMA 052 A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy Withdrawn USA 0
NCT05197322 Phase II Pembrolizumab NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NEOPRISM-CRC) Recruiting GBR 0
NCT05205330 Phase Ib/II Balstilimab + CR6086 A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients Active, not recruiting ITA 0
NCT05300048 Phase I Serabelisib Nab-paclitaxel + Serabelisib Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Active, not recruiting USA 0
NCT05308446 Phase II Cetuximab + Encorafenib Cetuximab + Encorafenib + Nivolumab Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation Recruiting USA 1
NCT05322590 Phase Ib/II BXQ-350 BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma (ASIST) Recruiting USA 0
NCT05356897 Phase II Trastuzumab + Trifluridine-tipiracil hydrochloride + Tucatinib Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study Not yet recruiting USA 0
NCT05379595 Phase Ib/II Amivantamab-vmjw Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1) Recruiting USA | ITA | ESP | DEU | CAN | BEL 5
NCT05400122 Phase I Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Suspended USA 0
NCT05425940 Phase III Atezolizumab + XL092 Regorafenib Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Recruiting USA | NZL | GBR | FRA | ESP | DEU | BEL | AUS 8
NCT05453825 Phase II Irinotecan + Navicixizumab Navicixizumab Navicixizumab + Paclitaxel A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors Recruiting USA 0
NCT05510895 Phase II Binimetinib + Cetuximab + Encorafenib Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF) Recruiting DEU 0
NCT05571293 Phase II Balstilimab + Botensilimab Combination Immunotherapy in Colorectal Cancer (NEST-1) Active, not recruiting USA 0
NCT05627635 Phase Ib/II Balstilimab + Bevacizumab + Botensilimab + Fluorouracil + Leucovorin + Oxaliplatin FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Recruiting USA 0
NCT05672316 Phase Ib/II Balstilimab + Botensilimab + Regorafenib Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy Recruiting USA 0
NCT05706779 Phase II Cetuximab + Encorafenib Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer (NEORAF) Recruiting FRA 0
NCT05710406 Phase II Cetuximab + Encorafenib Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer Recruiting USA 0
NCT05722327 Phase I Adagrasib + Cetuximab + Irinotecan Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer Recruiting USA 0
NCT05824559 Phase I Bevacizumab + ME-344 ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer Recruiting USA 0
NCT05870800 Phase II Atezolizumab + Capecitabine + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer Not yet recruiting USA 0
NCT05954871 Phase I Cetuximab + GDC-1971 GDC-1971 + Osimertinib Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer Recruiting USA | AUS 1
NCT05961709 Phase II Cemiplimab The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer Not yet recruiting USA 0
NCT05985954 Phase I Cetuximab + Encorafenib + Ulixertinib Cetuximab + Ulixertinib Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy Recruiting USA 0
NCT05999812 Phase II Atezolizumab + Bevacizumab + Tretinoin Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer Recruiting USA 0
NCT06011772 Phase I CIMAvax-EGF Bevacizumab + Cetuximab + CIMAvax-EGF + Leucovorin Bevacizumab + CIMAvax-EGF + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Irinotecan + Leucovorin EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer Recruiting USA 0
NCT06225843 Phase II AB-16B5 + Fluorouracil + Leucovorin + Oxaliplatin Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis (EGIA-003) Recruiting CAN 0